After more than a year of incubation, life-science venture firm Versant Ventures has launched Quanticel Pharmaceuticals Inc., a start-up with genomic analysis technology aimed at discovering and developing cancer drugs that target the unique genetic makeup of patients' tumor cells.
In an unusual arrangement that underscores the need to find new biotech investment models, Quanticel's only other investor is